MT-CO1

MT-CO1 encodes the catalytic core subunit of mitochondrial cytochrome c oxidase (complex IV), and mutations across its coding sequence impair complex IV electron transfer with downstream consequences for mitochondrial bioenergetics and redox state (PMID:23509693). Truncating mutations—both a heteroplasmic frameshift (m.7402delC) and a stop codon (m.6579G>A, p.Gly226X)—prematurely terminate the polypeptide and produce COX-negative muscle fibers with reduced complex IV activity, with single-fiber analysis showing co-segregation of high mutant load with COX deficiency (PMID:24956508, PMID:30743023). Missense and point mutations similarly compromise function, decreasing cytochrome oxidase activity, lowering mitochondrial membrane potential and ATP, and elevating reactive oxygen and nitrogen species (PMID:23509693, PMID:30207067). Beyond its catalytic role, the V83 region of MT-CO1 mediates protein–protein interactions with amyloid beta peptide and the neuroprotective protein UBQLN1, both of which are disrupted by the V83I (m.6150G>A) polymorphism (PMID:29610859). Ectopic over-expression of MT-CO1 drives a pro-cancerous metabolic phenotype—increased glucose uptake and lactate release, elevated ROS, and down-regulation of DNMT3A/DNMT3B with altered promoter CpG methylation—and MT-CO1 has been placed downstream of a RAS/MAPK pro-survival axis in hepatocellular carcinoma cells (PMID:31299394, PMID:34606010).

1. 2008 Low

   Established that MT-CO1 missense mutations can cause clinically distinct mitochondrial energy disorders beyond classical myopathy, broadening the phenotypic spectrum attributable to this subunit.

   Evidence Clinical phenotyping, mtDNA sequencing, and respiratory chain biochemistry in a single patient carrying m.6955G>A

   PMID:18484665

   Open questions at the time

   • Single patient case without in vitro reconstitution
   • No mechanistic dissection of the missense mutation's effect on complex IV assembly or activity
2. 2012 Medium

   Linked a patient-derived MT-CO1 mutation directly to impaired electron transfer and oxidative/nitrosative stress, connecting the subunit to redox dysregulation in cancer.

   Evidence Functional cellular assays of cytochrome oxidase activity, ROS, and reactive nitrogen in cells harboring a prostate-cancer-derived MT-CO1 mutation

   PMID:23509693

   Open questions at the time

   • No structural or reconstitution validation
   • Single lab, single study
3. 2014 Medium

   Demonstrated that a truncating frameshift mutation causally produces complex IV deficiency, establishing a direct genotype–biochemical–histological chain for MT-CO1 loss of function.

   Evidence NGS of mtDNA, COX histochemistry, spectrophotometric complex IV assay, and single-fiber PCR showing co-segregation of mutant load with COX-negative fibers

   PMID:24956508

   Open questions at the time

   • No reconstitution of the truncated protein's effect on assembly
   • Single pedigree
4. 2018 Medium

   Identified a non-catalytic interaction surface (V83 region) of MT-CO1 that binds amyloid beta and UBQLN1, and showed a natural polymorphism abolishes these interactions—pointing to a role beyond electron transfer.

   Evidence Yeast two-hybrid screen and ELISA comparing wild-type versus V83I binding

   PMID:29610859

   Open questions at the time

   • Interactions not validated in a cellular or mitochondrial context
   • Functional consequence of UBQLN1/Aβ binding to MT-CO1 unresolved
5. 2018 Low

   Tied a specific point mutation to the integrated mitochondrial dysfunction phenotype (raised ROS, depolarization, reduced ATP, increased apoptosis), connecting MT-CO1 variation to sepsis susceptibility.

   Evidence Family pedigree analysis with ROS, membrane potential, apoptosis, and ATP assays in carrier peripheral blood cells, with and without LPS

   PMID:30207067

   Open questions at the time

   • Primary cells from a single small pedigree
   • No biochemical reconstitution of the mutation's effect on complex IV
6. 2019 Medium

   Showed that MT-CO1 over-expression is not merely a passenger but can actively impose a pro-cancerous metabolic and epigenetic state, implicating the subunit as a driver of malignant reprogramming.

   Evidence Codon-optimized ectopic MT-CO1 expression with proliferation, metabolic, ROS, gene expression, and DNA methylation profiling

   PMID:31299394

   Open questions at the time

   • No structural validation; protein aggregated under denaturing conditions
   • No independent replication of the epigenetic effects
7. 2019 Low

   Confirmed that truncating MT-CO1 mutations can present as adult-onset Leigh syndrome, extending the clinical reach of subunit loss of function.

   Evidence Whole mitochondrial genome sequencing and COX histochemistry showing COX-deficient fibers in a patient with m.6579G>A (p.Gly226X)

   PMID:30743023

   Open questions at the time

   • Single patient case
   • No direct complex IV activity measurement
8. 2021 Low

   Placed MT-CO1 downstream of RAS/MAPK in a pro-survival/proliferation axis in hepatocellular carcinoma, suggesting it integrates oncogenic signaling with mitochondrial output.

   Evidence In vitro HCC photothermal nanocapsule treatment with proliferation, apoptosis, and motility assays implicating RAS/MAPK/MT-CO1

   PMID:34606010

   Open questions at the time

   • Pathway order inferred without genetic epistasis
   • Complex intervention provides only indirect evidence for MT-CO1's specific role

• How MT-CO1's non-catalytic interactions (Aβ, UBQLN1) and its over-expression-driven oncogenic phenotype mechanistically connect to its core role in complex IV electron transfer remains unresolved.
• No structural model linking V83-region binding to catalytic function
• Mechanism by which over-expressed MT-CO1 down-regulates DNMTs is unknown
• RAS/MAPK/MT-CO1 axis lacks direct biochemical validation